Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Taskus Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Taskus Inc trades at $5.12 (market cap $475.98M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 9.4× Taskus Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | TASK | |
|---|---|---|
Market Cap | $4.49B | $475.98M |
Sector | Health | Technology |
52-Week High | $28.06 | $18.21 |
52-Week Low | $20.06 | $4.57 |
Enterprise Value | $3.69B | $871.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TaskUs trades at $5.19, up 3.18% today, with a bearish technical signal despite strong fundamentals including a P/E of 4.59 and net income margin of 8.7%. Recent Q1 2026 earnings missed expectations, but revenue reached $1.18B in 2025. The company appointed a new CFO in June 2026 and reported growing interest in robotaxi services, indicating strategic positioning in digital customer experience.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. Risks include recent earnings volatility and competitive pressures in outsourcing services. Analyst sentiment is mixed with 55% buy ratings, suggesting cautious optimism amid near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
